Kado Karl, Forsyth Andrew, Patel Priyesh Ramesh, Schwartz Janice Ann
Wayne State University School of Medicine, 540 E. Canfield Detroit, MI 48201, USA.
Front Biosci (Elite Ed). 2012 Jan 1;4(1):546-67. doi: 10.2741/399.
The association between breast cancer and modifiable health behaviors is well supported. At least one-half of all cancers are suggested to have a dietary component. It is not surprising therefore that many of the dietary agents and natural health products that have attracted the attentions of scientists and practitioners are now moving into clinical trials. In this report, we review 65 clinical intervention trials evaluating over 30 dietary supplements and natural health products for use in breast cancer. The products being tested in these trials fall broadly into the following categories: (i) vitamins, minerals, cofactors; (ii) herbal extracts; (iii) amino acids; (iv) fatty acids; (v) animal products; (vi) probiotics; (vii) phytochemicals; and (viii) combination formulations. Trial outcome measures include risk modification, efficacy testing (with dietary supplements alone or dietary supplement-anticancer drug combinations), toxicity reduction, biomarker identification, symptom management, and quality of life parameters. The wide range of interests in natural product testing at the clinical trial level supports the potential utility of these agents in the breast cancer prevention, treatment, and management regimens of the future.
乳腺癌与可改变的健康行为之间的关联得到了充分支持。据推测，所有癌症中至少有一半与饮食因素有关。因此，许多引起科学家和从业者关注的饮食因子和天然健康产品如今进入临床试验阶段也就不足为奇了。在本报告中，我们回顾了65项临床干预试验，这些试验评估了30多种用于乳腺癌的膳食补充剂和天然健康产品。这些试验中所测试的产品大致可分为以下几类：（i）维生素、矿物质、辅助因子；（ii）草药提取物；（iii）氨基酸；（iv）脂肪酸；（v）动物产品；（vi）益生菌；（vii）植物化学物质；以及（viii）复方制剂。试验结果指标包括风险调整、疗效测试（单独使用膳食补充剂或膳食补充剂与抗癌药物联合使用）、毒性降低、生物标志物识别、症状管理以及生活质量参数。在临床试验层面，对天然产品测试的广泛兴趣支持了这些制剂在未来乳腺癌预防、治疗和管理方案中的潜在效用。
